How many Elranatamab clinical trials are there?

46 Elranatamab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 27 are actively recruiting participants. 7 are marked completed.

Are Elranatamab clinical trials recruiting in 2026?

Yes — 27 Elranatamab trials are actively recruiting in 2026, with 218 U.S. sites across 31 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Elranatamab being studied for?

Elranatamab is being studied for Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Relapsed or Refractory Multiple Myeloma, Multiple Myeloma (MM) and 34 more. The trials are grouped by indication on this page.

What phase is Elranatamab in?

Elranatamab clinical trials span 2 Phase 4, 5 Phase 3, 19 Phase 2, 7 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Elranatamab clinical trials?

The lead sponsor across the most Elranatamab trials is Pfizer, with 24 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Elranatamab Clinical Trials (2026): 46 Studies for Multiple Myeloma & Refractory Multiple Myeloma

Creator: Hipa.ai Research
Published: 2026-04-27T18:13:50.147Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

46 Elranatamab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 16 indications (including Multiple Myeloma & Refractory Multiple Myeloma) and 9,308 total planned enrollment. 5 Phase 3 Elranatamab trials and 19 Phase 2, 2 Phase 4 are listed. 31 Elranatamab clinical trials are actively recruiting at 218 U.S. sites across 31 states. Most recent activity: NCT06855121 (Dec 2037).

Where to Participate: All Elranatamab Trial Sites in the U.S. (218 sites across 31 states)

Every actively recruiting Elranatamabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	University of Alabama at Birmingham	Birmingham35294-3300	NCT06121843	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT06974786	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT06988488	Map
AL	Infirmary Cancer Care	Mobile36607	NCT06152575	Map
AZ	Western Regional Medical Center, Inc. dba. City of Hope Phoenix	Goodyear85338	NCT06152575	Map
AZ	Mayo Clinic in Arizona - Phoenix	Phoenix85054	NCT06121843	Map
CA	Beverly Hills Cancer Center	Beverly Hills90211	NCT06152575	Map
CA	Clovis Community Medical Center	Clovis93611	NCT06152575	Map
CA	Community Cancer Institute	Clovis93611	NCT06152575	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06121843	Map
CA	Clinical Research Advisors (Encino Satellite Location)	Encino91316	NCT06152575	Map
CA	Community Regional Medical Center	Fresno93721	NCT06152575	Map
CA	University of California San Francisco	Fresno93701	NCT06152575	Map
CA	Hoag Health Center Irvine	Irvine92618	NCT06152575	Map
CA	Hoag Hospital Irvine	Irvine92618	NCT06152575	Map
CA	University of California San Diego	La Jolla92037	NCT06711705	Map
CA	Clinical Research Advisors (Korea Town Satellite Location)	Los Angeles90020	NCT06152575	Map
CA	Clinical Research Advisors (West Hollywood Satellite Location)	Los Angeles90048	NCT06152575	Map
CA	Valkyrie Clinical Trials	Los Angeles90067	NCT06152575	Map
CA	Hoag Memorial Hospital Presbyterian	Newport Beach92663	NCT06152575	Map
CA	Mission Community Hospital (Satellite Site)	Panorama City91402	NCT06152575	Map
CA	University of California	Sacramento95817	NCT06152575	Map
CA	University of California Davis (UC Davis) Comprehensive Cancer Center	Sacramento95817	NCT06152575	Map
CO	Colorado Blood Cancer Institute	Denver80218	NCT06974786	Map
CO	UCHealth Harmony	Fort Collins80528	NCT06057402	Map
CO	UCHealth Harmony	Fort Collins80528	NCT06152575	Map
CO	UCHealth Poudre Valley Hospital	Fort Collins80524	NCT06057402	Map
CO	UCHealth Poudre Valley Hospital	Fort Collins80524	NCT06152575	Map
CO	UCHealth Greeley Hospital	Greeley80634	NCT06057402	Map
CO	UCHealth Greeley Hospital	Greeley80634	NCT06152575	Map
CO	Longs Peak Hospital	Longmont80504	NCT06057402	Map
CO	UCHealth Longs Peak Hospital	Longmont80504	NCT06152575	Map
CO	UCHealth Longs Peak Medical Center	Longmont80504	NCT06057402	Map
CO	UCHealth Longs Peak Medical Center	Longmont80504	NCT06152575	Map
CO	UCHealth - Medical Center of the Rockies	Loveland80538	NCT06057402	Map
CO	UCHealth - Medical Center of the Rockies	Loveland80538	NCT06152575	Map
CT	Yale New Haven Hospital-Smilow Cancer Center	New Haven06510	NCT06988488	Map
FL	Sylvester Comprehensive Cancer Center - Aventura	Aventura33180	NCT05020236	Map
FL	Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center	Coral Gables33146	NCT06057402	Map
FL	Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center	Coral Gables33146	NCT06152575	Map
FL	Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center	Coral Gables33146	NCT06215118	Map
FL	Sylvester Comprehensive Cancer Center - Coral Springs	Coral Springs33065	NCT05020236	Map
FL	University of Miami Hospital and Clinics - Deerfield Beach	Deerfield Beach33442	NCT05020236	Map
FL	University of Miami Hospital and Clinics - Deerfield Beach	Deerfield Beach33442	NCT06152575	Map
FL	University of Miami Hospital and Clinics Deerfield Beach	Deerfield Beach33442	NCT06057402	Map
FL	University of Miami Hospital and Clinics Deerfield Beach	Deerfield Beach33442	NCT06215118	Map
FL	Sylvester Comprehensive Cancer Center- Doral	Doral33166	NCT06152575	Map
FL	Sylvester Comprehensive Cancer Center- Doral	Doral33166	NCT06215118	Map
FL	Sylvester Comprehensive Cancer Center - Hollywood	Hollywood33021	NCT05020236	Map
FL	Sylvester Comprehensive Cancer Center - Hollywood	Hollywood33021	NCT06152575	Map
FL	Mayo Clinic in Florida	Jacksonville32224	NCT06121843	Map
FL	Baptist Hospital of Miami	Miami33176	NCT06152575	Map
FL	Miami Cancer Institute at Baptist Health, Inc.	Miami33176	NCT06152575	Map
FL	Sylvester Comprehensive Cancer Center	Miami33136	NCT06057402	Map
FL	Sylvester Comprehensive Cancer Center	Miami33136	NCT06152575	Map
FL	Sylvester Comprehensive Cancer Center	Miami33136	NCT06215118	Map
FL	Sylvester Comprehensive Cancer Center Kendall	Miami33176	NCT06215118	Map
FL	Sylvester Comprehensive Cancer Center- Kendall	Miami33176	NCT06152575	Map
FL	University of Miami	Miami33136	NCT06997081	Map
FL	University of Miami Hospital and Clinics	Miami33136	NCT05020236	Map
FL	University of Miami Hospital and Clinics	Miami33136	NCT06057402	Map
FL	University of Miami Hospital and Clinics	Miami33136	NCT06152575	Map
FL	University of Miami Hospital and Clinics	Miami33136	NCT06215118	Map
FL	University of Miami Hospital and Clinics - Griffin Cancer Research Building	Miami33136	NCT06057402	Map
FL	University of Miami Hospital and Clinics - Griffin Cancer Research Building	Miami33136	NCT06152575	Map
FL	BRCR Global	Plantation33322	NCT06152575	Map
FL	BRCR Medical Center Inc	Plantation33322	NCT06152575	Map
FL	Sylvester Comprehensive Cancer Center Plantation	Plantation33324	NCT06215118	Map
FL	BRCR Global - Tamarac	Tamarac33321	NCT06152575	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06947083	Map
GA	Emory University Hospital	Atlanta30322	NCT06215118	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06215118	Map
GA	Emory Winship Cancer Institute	Atlanta30322	NCT04068597	Map
GA	Northside Hospital	Atlanta30342	NCT06121843	Map
GA	Winship Cancer Institute	Atlanta30322	NCT06215118	Map
GA	Winship Cancer Institute, Emory University	Atlanta30322	NCT07280013	Map
IL	Endeavor Health - Swedish Hospital	Chicago60625	NCT06152575	Map
IL	Endeavor Health - Evanston Hospital	Evanston60201	NCT06152575	Map
IL	Endeavor Health - Glenbrook Hospital Ambulatory Care Center	Glenview60026	NCT06152575	Map
IL	Endeavor Health - Highland Park Hospital Health Center 1	Highland Park60035	NCT06152575	Map
IL	HSHS St. John's Hospital	Springfield62769	NCT06152575	Map
IL	Simmons Cancer Institute at SIU	Springfield62702	NCT06152575	Map
IL	Springfield Clinic Main Campus	Springfield62703	NCT06152575	Map
IL	Springfield Memorial Hospital	Springfield62781	NCT06152575	Map
IL	Midwestern Regional Medical Center, Inc. dba City of Hope Chicago	Zion60099	NCT06152575	Map
IN	Community Health Network	Indianapolis46227	NCT04068597	Map
IN	Community Health Network, Inc.	Indianapolis46227	NCT06152575	Map
IN	Community Health Network, Inc.	Indianapolis46250	NCT06152575	Map
IN	Community Health Network, Inc.	Indianapolis46256	NCT06152575	Map
IN	Indiana CTSI Clinical Research Center (ICRC)	Indianapolis46202	NCT06215118	Map
IN	Indiana University Health University Hospital	Indianapolis46202	NCT06215118	Map
IN	Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC)	Indianapolis46202	NCT06215118	Map
IA	University of Iowa	Iowa City52242	NCT06974786	Map
KS	American Oncology Partners, P.A. Dba MidAmerica Cancer Care	Kansas City66112	NCT06152575	Map
KS	Ascentist Doctors' Hospital	Leawood66211	NCT06152575	Map
KS	American Oncology Partners, P.A. Dba MidAmerica Cancer Care	Merriam66204	NCT06152575	Map
MD	University of Maryland	Baltimore21201	NCT06215118	Map
MD	The Center for Cancer and Blood Disorders (CCBD)	Bethesda20817	NCT04068597	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT06121843	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT06152575	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT06799026	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT06832865	Map
MA	Beth-Israel Deaconess Medical Center	Boston02215	NCT06138275	Map
MA	BIDMC Research Pharmacy	Boston02215	NCT06152575	Map
MA	Brigham and Women's Hospital	Boston02115	NCT06215118	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06569147	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06121843	Map
MA	Dana-Farber Cancer Institute	Boston02115	NCT06138275	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06215118	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06799026	Map
MA	Massachusetts General Hospital	Boston02114	NCT06138275	Map
MA	Massachusetts General Hospital	Boston02114	NCT06832865	Map
MA	Dana-Farber Cancer Institute - Chestnut Hill	Newton02459	NCT06215118	Map
MA	University of Massachusetts Chan Medical School	Worcester01655	NCT06215118	Map
MI	University of Michigan	Ann Arbor48109	NCT06057402	Map
MI	Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)	Detroit48202	NCT06057402	Map
MI	START Midwest	Grand Rapids49546	NCT07280013	Map
MN	Mayo Clinic in Rochester, Minnesota	Rochester55905	NCT06121843	Map
MO	American Oncology Partners, P.A. Dba MidAmerica Cancer Care	Belton64012	NCT06152575	Map
MO	MIVA Medical	Independence64057	NCT06152575	Map
MO	American Oncology Partners, P.A. Dba MidAmerica Cancer Care	Kansas City64132	NCT06152575	Map
MO	Kansas City VA Medical Center	Kansas City64128	NCT06152575	Map
NE	Bryan Medical Center	Lincoln68506	NCT06152575	Map
NE	NHO Revive Research Institute, LLC	Lincoln68506	NCT06152575	Map
NE	Methodist Hospital	Omaha68114	NCT06215118	Map
NE	Nebraska Cancer Specialists	Omaha68130	NCT04068597	Map
NE	Oncology Hematology West P.C. dba Nebraska Cancer - Methodist	Omaha68114	NCT06215118	Map
NE	Oncology Hematology West P.C. dba Nebraska Cancer Specialists	Omaha68130	NCT06215118	Map
NE	University of Nebraska Medical Center	Omaha68198-6846	NCT04068597	Map
NE	University Of Nebraska Medical Center	Omaha68198	NCT06121843	Map
NH	Dartmouth Hitchcock Medical Center	Lebanon03756	NCT06215118	Map
NJ	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT07454382	Map
NJ	MSK Basking Ridge	Basking Ridge07920	NCT05623020	Map
NJ	MSK Basking Ridge	Basking Ridge07920	NCT06215118	Map
NJ	Hackensack University Medical Center	Hackensack07601	NCT06988488	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center	Hackensack07601	NCT06121843	Map
NJ	Memorial Sloan Kettering Monmouth (All Protocol Activities)	Middletown07748	NCT07454382	Map
NJ	MSK Monmouth	Middletown07748	NCT05623020	Map
NJ	MSK Monmouth	Middletown07748	NCT06215118	Map
NJ	Memorial Sloan Kettering Bergen (All Protocol Activities)	Montvale07645	NCT07454382	Map
NJ	MSK Bergen	Montvale07645	NCT05623020	Map
NJ	MSK Bergen	Montvale07645	NCT06215118	Map
NJ	Atlantic Health System Morristown Medical Center	Morristown07960	NCT06152575	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT06121843	Map
NY	Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All Protocol Activities)	Commack11725	NCT07454382	Map
NY	MSK Commack	Commack11725	NCT05623020	Map
NY	MSK Commack	Commack11725	NCT06215118	Map
NY	Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison10604	NCT07454382	Map
NY	MSK Westchester	Harrison10604	NCT05623020	Map
NY	MSK Westchester	Harrison10604	NCT06215118	Map
NY	Northwell Health/ RJ Zuckerberg Cancer Center	Lake Success11042	NCT06152575	Map
NY	Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy	Long Island City11101	NCT06215118	Map
NY	North Shore University Hospital	Manhasset11030	NCT06152575	Map
NY	Long Island Jewish Medical Center	New Hyde Park11040	NCT06152575	Map
NY	Laura and Isaac Perlmutter Cancer Center	New York10016	NCT06121843	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06121843	Map
NY	Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).	New York10021	NCT05020236	Map
NY	Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).	New York10021	NCT05623020	Map
NY	Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).	New York10021	NCT06215118	Map
NY	Memorial Sloan Kettering Cancer Center - Main Campus	New York10065	NCT05020236	Map
NY	Memorial Sloan Kettering Cancer Center - Main Campus	New York10065	NCT05623020	Map
NY	Memorial Sloan Kettering Cancer Center - Main Campus	New York10065	NCT06215118	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT07454382	Map
NY	Memorial Sloan Kettering Cancer Center-Main Campus	New York10065	NCT05623020	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale11553	NCT07454382	Map
NY	MSK Nassau	Uniondale11553	NCT05623020	Map
NY	MSK Nassau	Uniondale11553	NCT06215118	Map
NC	University of North Carolina	Chapel Hill27599	NCT06974786	Map
NC	Brody school of Medicine at East Carolina University	Greenville27834	NCT06152575	Map
NC	ECU Health Medical Center	Greenville27834	NCT06152575	Map
ND	Sanford Fargo Medical Center	Fargo58102	NCT06152575	Map
OH	Oncology Hematology Care Clinical Trials, LLC	Cincinnati45211	NCT06152575	Map
OH	Oncology Hematology Care Clinical Trials, LLC	Cincinnati45236	NCT06152575	Map
OH	Oncology Hematology Care Clinical Trials, LLC	Cincinnati45242	NCT06152575	Map
OH	Oncology Hematology Care Clinical Trials, LLC	Cincinnati45245	NCT06152575	Map
OH	The Jewish Hospital	Cincinnati45236	NCT06152575	Map
OH	TriHealth Cancer Institute- Thomas Comprehensive Care Center	Cincinnati45242	NCT06152575	Map
OH	TriHealth Cancer Institute-Good Samaritan Hospital	Cincinnati45220	NCT06152575	Map
OH	Cleveland Clinic	Cleveland44195	NCT06152575	Map
OH	The Ohio State University- The James Cancer Hospital and Solove Research Institute	Columbus43210	NCT06974786	Map
PA	Penn Medicine - Abramson Cancer Center Perelman	Philadelphia19104	NCT04068597	Map
PA	AHN West Penn Hospital	Pittsburgh15224	NCT06152575	Map
RI	Brown University Health Cancer Institute	Providence02903	NCT06152575	Map
RI	The Miriam Hospital	Providence02906	NCT06152575	Map
TN	Ascension St. Thomas Hospital	Nashville37203	NCT06152575	Map
TN	SCRI Oncology Partners	Nashville37203	NCT06974786	Map
TN	Tennessee Oncology	Nashville37203	NCT06121843	Map
TN	Tennessee Oncology, PLLC - Investigational Drug Services	Nashville37203	NCT06152575	Map
TN	Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers	Nashville37203	NCT06152575	Map
TN	Tennessee Oncology, PLLC - Nashville Elliston Place Plaza DDU	Nashville37203	NCT06152575	Map
TN	Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology	Nashville37203	NCT06152575	Map
TX	St. David's South Austin Medical Center	Austin78704	NCT06057402	Map
TX	Baylor University Medical Center	Dallas75246	NCT06152575	Map
TX	Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy	Dallas75246	NCT06152575	Map
TX	University of Texas Southwestern	Dallas75390	NCT06974786	Map
TX	Houston Methodist Cancer Center Infusion	Houston77030	NCT06152575	Map
TX	Houston Methodist Clear Lake Hospital (St. John)	Houston77058	NCT06152575	Map
TX	Houston Methodist Hospital - Department of Pharmacy	Houston77030	NCT06152575	Map
TX	Houston Methodist Hospital Cancer Center	Houston77030	NCT06152575	Map
TX	Houston Methodist West Hospital	Houston77094	NCT06152575	Map
TX	Houston Methodist Willowbrook Hospital	Houston77070	NCT06152575	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06207799	Map
TX	MD Anderson Cancer Center	Houston77030	NCT07382739	Map
TX	University of Texas MD Anderson Cancer Center	Houston77030	NCT06121843	Map
TX	University of Texas MD Anderson Cancer Center	Houston77030	NCT06988488	Map
TX	Joe Arrington Cancer Research and Treatment Center	Lubbock79410	NCT06152575	Map
TX	Houston Methodist Sugar Land Hospital	Sugar Land77479	NCT06152575	Map
TX	Baylor Scott & White Medical Center - Temple	Temple76508	NCT06152575	Map
TX	Houston Methodist The Woodlands Hospital	The Woodlands77385	NCT06152575	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT06974786	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT06215118	Map
WA	University of Washington	Seattle98195	NCT06215118	Map
WV	WVU Cancer Institute	Morgantown26506	NCT06152575	Map
WI	University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	Madison53718	NCT06152575	Map
WI	University of Wisconsin Carbone Cancer Center-University Hospital	Madison53792	NCT06152575	Map
WI	University of Wisconsin Clinical Science Center	Madison53792	NCT06974786	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06215118	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06974786	Map

Elranatamab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	not yet recruiting	no longer available	Total
P1	5	1	1				7
P1/P2	4						4
P2	12	2	2	1	2		19
P3	4	1					5
P4	1				1		2
N/A	1	1	4		1	2	9

Recruiting Elranatamab clinical trials (31)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06855121	NIMMSThe Norwegian Immunotherapy in Multiple Myeloma Study	—	Myeloma Multiple	400	Jan 2025
NCT07474961	BLOOD-doseBLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.	P4	Waldenstrom Macroglobulinaemia	400	Mar 2027
NCT06918002	ElLenElranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients	P3	Multiple Myeloma, Newly Diagnosed	824	Jul 2025
NCT07247097	ELDORADOELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma	P2	Multiple Myeloma	160	Apr 2026
NCT05623020	MagnetisMM-6A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant	P3	Multiple Myeloma	1,116	Nov 2022
NCT06974786	FASTERFrontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma	P2	Multiple Myeloma, Newly Diagnosed	100	Aug 2025
NCT06057402	MagnetisMM15Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)	P4	Multiple Myeloma	80	Oct 2023
NCT06207799	Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma	P2	Multiple Myeloma	40	Jul 2024
NCT06931704	IFM 2024_06Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)	P2	Multiple Myeloma	176	May 2025
NCT06183489	ERASMMUse of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma	P2	Smoldering Multiple Myeloma	50	May 2024
NCT07382739	RRMMA Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"	P2	Phase 2	34	Mar 2026
NCT06711705	Elranatamab in Relapsed/Refractory Multiple Myeloma	P2	Multiple Myeloma	33	Dec 2024
NCT06997081	ERd Combination Treatment in Newly Diagnosed Multiple Myeloma	P2	Multiple Myeloma	104	Sep 2025
NCT06799026	DCA Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma	P1	Multiple Myeloma	25	Jan 2025
NCT06569147	Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis	P1/P2	AL Amyloidosis	49	Nov 2024
NCT07454382	A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma	P2	Multiple Myeloma	26	Feb 2026
NCT07280013	A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects	P1	Multiple Myeloma (MM)	60	Feb 2026
NCT06947083	Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma	P2	Myeloma	39	May 2025
NCT06421675	EMBRACEOutpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma	P2	Refractory Multiple Myeloma	40	Mar 2025
NCT06832865	ELISA in Relapsed/Refractory MM	P2	Relapsed Refractory Multiple Myeloma (RRMM)	30	Aug 2025
NCT06138275	Elranatamab in R/R Multiple Myeloma	P2	Refractory Multiple Myeloma	32	Mar 2024
NCT07320326	ASPIREASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab	—	TCE-RRMM	159	Dec 2025
NCT06121843	BMS-986393A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma	P1	Multiple Myeloma	147	Feb 2024
NCT06215118	PF-06863135A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)	P1	Multiple Myeloma	87	Feb 2024
NCT06152575	MMMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)	P3	Multiple Myeloma	492	Feb 2024
NCT06645678	MELT-MMMezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma	P1/P2	Relapsed Refractory Multiple Myeloma (RRMM)	75	Nov 2024
NCT05927571	A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)	P1	Relapsed or Refractory Multiple Myeloma	120	Aug 2023
NCT06015542	ERICASelf-administration of Subcutaneous Elranatamab in the Patients' Homes.	P2	Multiple Myeloma	20	Jan 2025
NCT06988488	A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma	P1/P2	Multiple Myeloma	62	Oct 2025
NCT05020236	MAGNETISMM-5A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments	P3	Multiple Myeloma	944	Oct 2021
NCT04068597	Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies	P1/P2	Haematological Malignancy	250	Aug 2019

Elranatamab clinical trials by indication

Multiple Myeloma (27)

NCT	Acronym	Phase	Status	Title
NCT07247097	ELDORADO	P2	not yet recruiting	ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
NCT05623020	MagnetisMM-6	P3	recruiting	A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT06057402	MagnetisMM15	P4	recruiting	Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06207799	—	P2	recruiting	Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
NCT06931704	IFM 2024_06	P2	not yet recruiting	Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
NCT06711705	—	P2	recruiting	Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06997081	—	P2	recruiting	ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
NCT06799026	DC	P1	recruiting	A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
+ 19 more, see All trials below.

Relapsed Refractory Multiple Myeloma (RRMM) (2)

NCT	Acronym	Phase	Status	Title
NCT06832865	—	P2	recruiting	ELISA in Relapsed/Refractory MM
NCT06645678	MELT-MM	P1/P2	recruiting	Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma, Newly Diagnosed (2)

NCT	Acronym	Phase	Status	Title
NCT06918002	ElLen	P3	recruiting	Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT06974786	FASTER	P2	recruiting	Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Refractory Multiple Myeloma (2)

NCT	Acronym	Phase	Status	Title
NCT06421675	EMBRACE	P2	recruiting	Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06138275	—	P2	recruiting	Elranatamab in R/R Multiple Myeloma

Relapsed or Refractory Multiple Myeloma (2)

NCT	Acronym	Phase	Status	Title
NCT05927571	—	P1	recruiting	A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
NCT04798586	PF-06863135	P1	completed	MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Waldenstrom Macroglobulinaemia (1)

NCT	Acronym	Phase	Status	Title
NCT07474961	BLOOD-dose	P4	not yet recruiting	BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

Phase 2 (1)

NCT	Acronym	Phase	Status	Title
NCT07382739	RRMM	P2	recruiting	A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Multiple Myeloma (MM) (1)

NCT	Acronym	Phase	Status	Title
NCT07280013	—	P1	recruiting	A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

TCE-RRMM (1)

NCT	Acronym	Phase	Status	Title
NCT07320326	ASPIRE	N/A	not yet recruiting	ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT06947083	—	P2	recruiting	Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

Myeloma Multiple (1)

NCT	Acronym	Phase	Status	Title
NCT06855121	NIMMS	N/A	recruiting	The Norwegian Immunotherapy in Multiple Myeloma Study

AL Amyloidosis (1)

NCT	Acronym	Phase	Status	Title
NCT06569147	—	P1/P2	recruiting	Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Smoldering Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT06183489	ERASMM	P2	recruiting	Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Multiple Myeloma in Relapse (1)

NCT	Acronym	Phase	Status	Title
NCT06282978	—	P2	active not recruiting	Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Elranatamab (1)

NCT	Acronym	Phase	Status	Title
NCT05228470	PF-06863135	P2	completed	A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Haematological Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT04068597	—	P1/P2	recruiting	Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Elranatamab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
BLOOD-dose	NCT07474961	P4	not yet recruiting	Waldenstrom Macroglobulinaemia	400	—
MagnetisMM15	NCT06057402	P4	recruiting	Multiple Myeloma	80	—
ElLen	NCT06918002	P3	recruiting	Multiple Myeloma, Newly Diagnosed	824	—
MagnetisMM-6	NCT05623020	P3	recruiting	Multiple Myeloma	1,116	—
MagnetisMM-7	NCT05317416	P3	active not recruiting	Multiple Myeloma	854	—
MM	NCT06152575	P3	recruiting	Multiple Myeloma	492	—
MAGNETISMM-5	NCT05020236	P3	recruiting	Multiple Myeloma	944	—
ELDORADO	NCT07247097	P2	not yet recruiting	Multiple Myeloma	160	—
FASTER	NCT06974786	P2	recruiting	Multiple Myeloma, Newly Diagnosed	100	—
IFM 2024_06	NCT06931704	P2	not yet recruiting	Multiple Myeloma	176	—
ERASMM	NCT06183489	P2	recruiting	Smoldering Multiple Myeloma	50	—
RRMM	NCT07382739	P2	recruiting	Phase 2	34	—
EMBRACE	NCT06421675	P2	recruiting	Refractory Multiple Myeloma	40	—
ERICA	NCT06015542	P2	recruiting	Multiple Myeloma	20	—
PF-06863135	NCT04649359	P2	active not recruiting	Multiple Myeloma	187	—
PF-06863135	NCT05090566	P2	terminated	Multiple Myeloma	46	—
MagnetisMM-9	NCT05014412	P2	completed	Multiple Myeloma	86	—
PF-06863135	NCT05228470	P2	completed	Elranatamab	39	—

Terminated and withdrawn Elranatamab trials (1)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05090566terminatedMagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

All Elranatamab trials (46)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06855121	NIMMS	The Norwegian Immunotherapy in Multiple Myeloma Study	—	recruiting	400	St. Olavs Hospital	Jan 2025
NCT07474961	BLOOD-dose	BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.	P4	not yet recruiting	400	Anne Louise Tølbøll Sørensen	Mar 2027
NCT06918002	ElLen	Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients	P3	recruiting	824	Intergroupe Francophone du Myelome	Jul 2025
NCT07247097	ELDORADO	ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma	P2	not yet recruiting	160	Massachusetts General Hospital	Apr 2026
NCT05623020	MagnetisMM-6	A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant	P3	recruiting	1,116	Pfizer	Nov 2022
NCT06974786	FASTER	Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma	P2	recruiting	100	SCRI Development Innovations, LLC	Aug 2025
NCT06057402	MagnetisMM15	Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)	P4	recruiting	80	Pfizer	Oct 2023
NCT06207799		Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma	P2	recruiting	40	M.D. Anderson Cancer Center	Jul 2024
NCT06931704	IFM 2024_06	Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)	P2	not yet recruiting	176	Nantes University Hospital	May 2025
NCT06183489	ERASMM	Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma	P2	recruiting	50	Stichting European Myeloma Network	May 2024
NCT07382739	RRMM	A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"	P2	recruiting	34	M.D. Anderson Cancer Center	Mar 2026
NCT06711705		Elranatamab in Relapsed/Refractory Multiple Myeloma	P2	recruiting	33	University of California, San Diego	Dec 2024
NCT06997081		ERd Combination Treatment in Newly Diagnosed Multiple Myeloma	P2	recruiting	104	University of Miami	Sep 2025
NCT06799026	DC	A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma	P1	recruiting	25	David Avigan	Jan 2025
NCT06581848		Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).	—	active not recruiting	150	Pfizer	Jun 2025
NCT06282978		Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes	P2	active not recruiting	50	PETHEMA Foundation	Nov 2023
NCT05317416	MagnetisMM-7	Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant	P3	active not recruiting	854	Pfizer	Mar 2022
NCT06569147		Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis	P1/P2	recruiting	49	Brigham and Women's Hospital	Nov 2024
NCT07454382		A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma	P2	recruiting	26	Memorial Sloan Kettering Cancer Center	Feb 2026
NCT07280013		A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects	P1	recruiting	60	C4 Therapeutics, Inc.	Feb 2026
NCT06947083		Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma	P2	recruiting	39	H. Lee Moffitt Cancer Center and Research Institute	May 2025
NCT06421675	EMBRACE	Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma	P2	recruiting	40	Ontario Clinical Oncology Group (OCOG)	Mar 2025
NCT06832865		ELISA in Relapsed/Refractory MM	P2	recruiting	30	Massachusetts General Hospital	Aug 2025
NCT06138275		Elranatamab in R/R Multiple Myeloma	P2	recruiting	32	Massachusetts General Hospital	Mar 2024
NCT07320326	ASPIRE	ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab	—	not yet recruiting	159	Peking University People's Hospital	Dec 2025
NCT06121843	BMS-986393	A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma	P1	recruiting	147	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Feb 2024
NCT06215118	PF-06863135	A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)	P1	recruiting	87	Pfizer	Feb 2024
NCT05675449	MagnetisMM-20	A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma	P1	active not recruiting	59	Pfizer	Dec 2022
NCT06152575	MM	MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)	P3	recruiting	492	Pfizer	Feb 2024
NCT06645678	MELT-MM	Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma	P1/P2	recruiting	75	YOUNGIL KOH	Nov 2024
NCT05927571		A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)	P1	recruiting	120	Genentech, Inc.	Aug 2023
NCT06015542	ERICA	Self-administration of Subcutaneous Elranatamab in the Patients' Homes.	P2	recruiting	20	Thomas Lund	Jan 2025
NCT06988488		A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma	P1/P2	recruiting	62	Celgene	Oct 2025
NCT05020236	MAGNETISMM-5	A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments	P3	recruiting	944	Pfizer	Oct 2021
NCT04068597		Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies	P1/P2	recruiting	250	CellCentric Ltd.	Aug 2019
NCT04649359	PF-06863135	MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb	P2	active not recruiting	187	Pfizer	Feb 2021
NCT05090566	PF-06863135	MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma	P2	terminated	46	Pfizer	Oct 2021
NCT05014412	MagnetisMM-9	A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment	P2	completed	86	Pfizer	Oct 2021
NCT05228470	PF-06863135	A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.	P2	completed	39	Pfizer	Dec 2021
NCT06592222		A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies	—	completed	4	Pfizer	Aug 2024
NCT06504524	PF 06863135	A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US	—	completed	633	Pfizer	Sep 2023
NCT05932290		A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma	—	completed	514	Pfizer	Jun 2023
NCT04798586	PF-06863135	MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma	P1	completed	4	Pfizer	Mar 2021
NCT05565391		A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma	—	completed	508	Pfizer	Oct 2022
NCT05462639	MAGNETISMM17	Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma	—	no longer available	0	Pfizer	—
NCT05238311	PF-06863135	Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)	—	no longer available	0	Pfizer	—

Elranatamab clinical trials: frequently asked questions

How many Elranatamab clinical trials are there?: 46 Elranatamab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 27 are actively recruiting participants. 7 are marked completed.
Are Elranatamab clinical trials recruiting in 2026?: Yes — 27 Elranatamab trials are actively recruiting in 2026, with 218 U.S. sites across 31 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Elranatamab being studied for?: Elranatamab is being studied for Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Relapsed or Refractory Multiple Myeloma, Multiple Myeloma (MM) and 34 more. The trials are grouped by indication on this page.
What phase is Elranatamab in?: Elranatamab clinical trials span 2 Phase 4, 5 Phase 3, 19 Phase 2, 7 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Elranatamab clinical trials?: The lead sponsor across the most Elranatamab trials is Pfizer, with 24 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Elranatamabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

Elranatamab overview